Belgium has amended its pharmaceutical reimbursement procedures and established a separate category for unregistered medicines whose eligibility depends on a qualifying predictive test.
Belgium has amended its statutory medicine reimbursement procedures, creating Chapter VIII-bis for specified unregistered medicines linked to predictive diagnostic tests. A royal decree of 4 October, published on 12 October, takes effect on 1 November 2026.
Existing Chapter VIII covers reimbursed medicines for which a predictive test establishes whether the patient satisfies a treatment condition. Chapter IV-bis separately covers certain unregistered medicines. The new Chapter VIII-bis combines these features: it provides a route for an unregistered medicine when the associated predictive marker meets the prescribed diagnostic reimbursement criteria.
The amended rules require lawful prescribing, importation and supply, with prior approval by the health insurer's medical adviser. Reimbursement is calculated from the invoice price, including relevant taxes and duties, plus the permitted pharmacist margin; patient contributions remain applicable. Authorisations can last up to 12 months and may be renewed on justified request.
The decree also revises aspects of the application procedure, including arrangements for biosimilars, parallel distribution, hearings and technical reimbursement-list corrections. Applications submitted before commencement continue under the previous rules.
Chapter VIII-bis establishes a legal category; practical coverage will depend on the medicines, biomarkers and conditions subsequently included in the reimbursement list. Its immediate effect is therefore procedural, with eligibility determined by the listed criteria.
Source: Belgian Official Gazette
Link: Arrêté royal du 4 octobre 2026 modifiant l’arrêté royal du 1er février 2018 fixant les procédures, délais et conditions en matière d’intervention de l’assurance obligatoire soins de santé et indemnités dans le coût des spécialités pharmaceutiques (Royal Decree of 4 October 2026 amending procedures and conditions for reimbursement of pharmaceutical specialities)
Date: 12 October 2026
Please accept {{cookieConsents}} cookies to view this content